THANZY PHARM SOLUTIONS LIMITED

Company Registration Number:
09668302 (England and Wales)

Unaudited statutory accounts for the year ended 31 July 2023

Period of accounts

Start date: 01 August 2022

End date: 31 July 2023

THANZY PHARM SOLUTIONS LIMITED

Contents of the Financial Statements

for the Period Ended 31 July 2023

Company Information - 3
Report of the Directors - 4
Balance sheet - 5
Additional notes - 7
Balance sheet notes - 10

THANZY PHARM SOLUTIONS LIMITED

Company Information

for the Period Ended 31 July 2023




Director: THANDAZANI NCUBE
Registered office: 3
Mokyll Croft
Taverham
Norwich
England
NR8 6UG
Company Registration Number: 09668302 (England and Wales)

THANZY PHARM SOLUTIONS LIMITED

Directors' Report Period Ended 31 July 2023

The directors present their report with the financial statements of the company for the period ended 31 July 2023

Principal Activities

Provision of scientific and technical services.

Directors

The directors shown below have held office during the whole of the period from 01 August 2022 to 31 July 2023
THANDAZANI NCUBE

This report was approved by the board of directors on 12 November 2023
And Signed On Behalf Of The Board By:

Name: THANDAZANI NCUBE
Status: Director

THANZY PHARM SOLUTIONS LIMITED

Balance sheet

As at 31 July 2023


Notes

2023
£

2022
£
Fixed assets
Tangible assets: 4 2,133 6,183
Total fixed assets: 2,133 6,183
Current assets
Debtors: 5 466 925
Total current assets: 466 925
Prepayments and accrued income: 202 924
Creditors: amounts falling due within one year: 6 ( 650 ) ( 650 )
Net current assets (liabilities): 18 1,199
Total assets less current liabilities: 2,151 7,382
Creditors: amounts falling due after more than one year: 7 ( 16,521 ) ( 11,250 )
Total net assets (liabilities): ( 14,370 ) ( 3,868 )

The notes form part of these financial statements

THANZY PHARM SOLUTIONS LIMITED

Balance sheet continued

As at 31 July 2023


Notes

2023
£

2022
£
Capital and reserves
Called up share capital: 100 100
Profit and loss account: ( 14,470 ) ( 3,968 )
Shareholders funds: ( 14,370 ) ( 3,868 )

For the year ending 31 July 2023 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 12 November 2023
And Signed On Behalf Of The Board By:

Name: THANDAZANI NCUBE
Status: Director

The notes form part of these financial statements

THANZY PHARM SOLUTIONS LIMITED

Notes to the Financial Statements

for the Period Ended 31 July 2023

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

THANZY PHARM SOLUTIONS LIMITED

Notes to the Financial Statements

for the Period Ended 31 July 2023

  • 2. Employees


    2023

    2022
    Average number of employees during the period 1 1

THANZY PHARM SOLUTIONS LIMITED

Notes to the Financial Statements

for the Period Ended 31 July 2023

  • 3. Off balance sheet disclosure

    No

THANZY PHARM SOLUTIONS LIMITED

Notes to the Financial Statements

for the Period Ended 31 July 2023

4. Tangible assets

Office equipment Motor vehicles Total
Cost £ £ £
At 01 August 2022 11,640 10,673 22,313
Additions - - -
Disposals - - -
Revaluations - - -
Transfers - - -
At 31 July 2023 11,640 10,673 22,313
Depreciation
At 01 August 2022 9,725 6,405 16,130
Charge for year 1,915 2,135 4,050
On disposals - - -
Other adjustments - - -
At 31 July 2023 11,640 8,540 20,180
Net book value
At 31 July 2023 0 2,133 2,133
At 31 July 2022 1,915 4,268 6,183

THANZY PHARM SOLUTIONS LIMITED

Notes to the Financial Statements

for the Period Ended 31 July 2023

5. Debtors


2023
£

2022
£
Trade debtors 202 925
Prepayments and accrued income 264
Total 466 925

THANZY PHARM SOLUTIONS LIMITED

Notes to the Financial Statements

for the Period Ended 31 July 2023

6.Creditors: amounts falling due within one year note


2023
£

2022
£
Other creditors 650 650
Total 650 650

THANZY PHARM SOLUTIONS LIMITED

Notes to the Financial Statements

for the Period Ended 31 July 2023

7.Creditors: amounts falling due after more than one year


2023
£

2022
£
Bank loans and overdrafts 7,988 11,250
Other creditors 8,533
Total 16,521 11,250